Loading clinical trials...
Loading clinical trials...
The Safety and Efficacy of Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Squamous Cell Carcinoma.
Conditions
Interventions
Camrelizumab
Locations
1
China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Start Date
November 10, 2021
Primary Completion Date
September 30, 2023
Completion Date
November 1, 2026
Last Updated
November 19, 2025
NCT06719440
NCT05689463
NCT07325721
NCT05926765
NCT06330142
NCT06488950
Lead Sponsor
Fujian Medical University Union Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions